NanoVibronix stock plunges to 52-week low at $1.14

Published 22/05/2025, 15:26
NanoVibronix stock plunges to 52-week low at $1.14

In a challenging year for NanoVibronix, the medical device company’s stock has tumbled to $1.14, near its 52-week low. With a market capitalization of just $0.87 million and annual revenue of $2.56 million, the company faces significant headwinds. According to InvestingPro analysis, the stock appears undervalued at current levels. This latest price level reflects a stark downturn in investor sentiment as the company grapples with market headwinds. Over the past year, NanoVibronix has seen its stock value erode dramatically, with a 1-year total return of -85.31%. While the company maintains more cash than debt on its balance sheet, InvestingPro data reveals rapid cash burn and negative EBITDA of -$3.58 million. The significant drop underscores the hurdles the company faces, as it struggles to regain its footing in a competitive and rapidly evolving industry. Unlock 12 additional InvestingPro Tips to gain deeper insights into NanoVibronix’s financial health and market position.

In other recent news, NanoVibronix, Inc. announced the pricing of a public offering expected to raise approximately $10 million before fees and expenses. The offering includes Series G Convertible Preferred Stock and Warrants, with the funds intended for debt redemption and general corporate purposes. Additionally, the company has regained compliance with Nasdaq’s listing requirements, ensuring its continued presence on the Nasdaq Capital Market. This follows a previous risk of delisting due to not meeting minimum bid price and stockholders’ equity requirements. NanoVibronix also secured a $360,000 promissory note with Alpha Capital Anstalt, which carries an 8% annual interest rate and is due in June 2025.

Furthermore, the company expanded its distribution agreement with Dukehill Healthcare Pty Ltd. to cover all Australian states, following increased demand for its UroShield device. This expansion is supported by a recent independent study highlighting UroShield’s effectiveness in reducing catheter-associated complications. In governance news, board member Aurora Cassirer resigned from the board of directors, with the company noting the resignation was not due to any disagreements. These developments are part of NanoVibronix’s ongoing efforts to strengthen its financial and operational standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.